GlaxoSmithKline (LSE: GSK) has reported promising results from trials of its latest vaccine, HZ/su, which treats shingles. While it’s only one vaccine and Glaxo needs to find many more in the years to come to shore up profits, shareholders will hope it’s a small vindication of the company’s decision to double down on vaccines.
Does GlaxoSmithKline plc’s Latest Treatment Point To Its Future?
VIDEO: One Fool takes a closer look at GlaxoSmithKline plc (LON:GSK).
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.